Phase I relative bioavailability and food effect study

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002813-24

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objectives of this study are to •investigate the relative bioavailability of a single oral dose of 20 mg finerenone suspension and 20 mg crushed and resuspended tablet in comparison to 20 mg finerenone tablet in the fasting condition •investigate the effect of a high fat, high calorie meal on the pharmacokinetics after a single oral dose of 20 mg finerenone suspension •investigate whether 20 mg finerenone suspension and 20 mg crushed and resuspended tablet are palatable and swallowable


Critère d'inclusion

  • Diabetic Kidney Disease

Liens